CO2019009020A2 - Derivados de pirazol como inhibidores de bromodominio. - Google Patents
Derivados de pirazol como inhibidores de bromodominio.Info
- Publication number
- CO2019009020A2 CO2019009020A2 CONC2019/0009020A CO2019009020A CO2019009020A2 CO 2019009020 A2 CO2019009020 A2 CO 2019009020A2 CO 2019009020 A CO2019009020 A CO 2019009020A CO 2019009020 A2 CO2019009020 A2 CO 2019009020A2
- Authority
- CO
- Colombia
- Prior art keywords
- pyrazole derivatives
- bromodomain inhibitors
- compounds
- bromodomain
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
La presente invención se refiere a derivados de pirazol, a composiciones farmacéuticas que comprenden los compuestos y al uso de los compuestos o de las composiciones en el tratamiento de diversas enfermedades.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1703283.0A GB201703283D0 (en) | 2017-03-01 | 2017-03-01 | Compounds |
GBGB1716374.2A GB201716374D0 (en) | 2017-10-06 | 2017-10-06 | Compounds |
PCT/EP2018/054733 WO2018158212A1 (en) | 2017-03-01 | 2018-02-27 | Pyrazole derivatives as bromodomain inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2019009020A2 true CO2019009020A2 (es) | 2019-08-30 |
Family
ID=61691917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2019/0009020A CO2019009020A2 (es) | 2017-03-01 | 2019-08-21 | Derivados de pirazol como inhibidores de bromodominio. |
Country Status (22)
Country | Link |
---|---|
US (1) | US10966961B2 (es) |
EP (1) | EP3589618B1 (es) |
JP (1) | JP6857254B2 (es) |
KR (1) | KR102403176B1 (es) |
CN (1) | CN110582485B (es) |
AU (1) | AU2018228651B2 (es) |
BR (1) | BR112019018028A2 (es) |
CA (1) | CA3054754A1 (es) |
CL (1) | CL2019002480A1 (es) |
CO (1) | CO2019009020A2 (es) |
CR (1) | CR20190391A (es) |
DO (1) | DOP2019000221A (es) |
ES (1) | ES2938269T3 (es) |
IL (1) | IL268565B (es) |
JO (1) | JOP20190192A1 (es) |
MX (1) | MX2019010218A (es) |
PE (1) | PE20191535A1 (es) |
PH (1) | PH12019501999A1 (es) |
SG (1) | SG11201907546WA (es) |
TW (1) | TW201841893A (es) |
UY (1) | UY37622A (es) |
WO (1) | WO2018158212A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201814167D0 (en) * | 2018-08-31 | 2018-10-17 | Glaxosmithkline Ip No 2 Ltd | Compounds |
CN113402428B (zh) * | 2021-06-11 | 2023-03-03 | 重庆医药高等专科学校 | 一种反式4-(叔丁氧羰氨基)环己烷羧酸及其中间体的制备方法 |
WO2024018423A1 (en) | 2022-07-21 | 2024-01-25 | Tay Therapeutics Limited | Pyrroles and imidazoles as bet protein inhibitors |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE438624T1 (de) | 2000-12-28 | 2009-08-15 | Shionogi & Co | 2-pyridonderivate mit affinität für den cannabinoid-typ-2-rezeptor |
EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
DE60318089T2 (de) | 2002-10-09 | 2008-12-04 | Critical Outcome Technologies, Inc. | Protein-tyrosine-kinase-inhibitoren |
US7429581B2 (en) * | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
EP1433788A1 (en) * | 2002-12-23 | 2004-06-30 | Aventis Pharma Deutschland GmbH | Pyrazole-derivatives as factor Xa inhibitors |
DE60329529D1 (de) * | 2002-12-23 | 2009-11-12 | Sanofi Aventis Deutschland | Pyrazolderivate als faktor-xa-inhibitoren |
CN101490273A (zh) * | 2006-05-09 | 2009-07-22 | 南卡罗来纳州医科大学研究发展基金会 | 利用蛋白酶和蛋白酶抑制剂血浆分析检测舒张期心力衰竭 |
AR075594A1 (es) * | 2009-02-26 | 2011-04-20 | Glaxo Group Ltd | Derivados de ( 2-tienil)-sulfonil-amino-1h-indazol como antagonistas de ccr4 |
GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
AR084070A1 (es) * | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
US9657009B2 (en) | 2012-11-08 | 2017-05-23 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
JP2016507496A (ja) * | 2012-12-21 | 2016-03-10 | ゼニス・エピジェネティクス・コーポレイションZenith Epigenetics Corp. | ブロモドメイン阻害剤としての新規複素環式化合物 |
KR20160038008A (ko) | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
WO2017037116A1 (en) | 2015-09-02 | 2017-03-09 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
CN108290866B (zh) | 2015-10-05 | 2020-12-18 | 葛兰素史克知识产权第二有限公司 | 作为溴结构域抑制剂的2-氧代-1,2-二氢吡啶-3,5-二甲酰胺化合物 |
CN105523955B (zh) * | 2015-12-14 | 2018-08-17 | 北京嘉林药业股份有限公司 | 化合物及其在制备药物中的用途 |
KR20180132682A (ko) | 2016-04-07 | 2018-12-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 브로모도메인 억제제로서의 피리딜 유도체 |
WO2017202742A1 (en) | 2016-05-24 | 2017-11-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridine dicarboxamide derivatives as bromodomain inhibitors |
-
2017
- 2017-06-16 JO JOP/2019/0192A patent/JOP20190192A1/ar unknown
-
2018
- 2018-02-27 JP JP2019547351A patent/JP6857254B2/ja active Active
- 2018-02-27 PE PE2019001785A patent/PE20191535A1/es unknown
- 2018-02-27 UY UY0001037622A patent/UY37622A/es not_active Application Discontinuation
- 2018-02-27 WO PCT/EP2018/054733 patent/WO2018158212A1/en unknown
- 2018-02-27 KR KR1020197028575A patent/KR102403176B1/ko active IP Right Grant
- 2018-02-27 US US16/489,859 patent/US10966961B2/en active Active
- 2018-02-27 BR BR112019018028-1A patent/BR112019018028A2/pt unknown
- 2018-02-27 CR CR20190391A patent/CR20190391A/es unknown
- 2018-02-27 MX MX2019010218A patent/MX2019010218A/es unknown
- 2018-02-27 AU AU2018228651A patent/AU2018228651B2/en active Active
- 2018-02-27 ES ES18712082T patent/ES2938269T3/es active Active
- 2018-02-27 SG SG11201907546WA patent/SG11201907546WA/en unknown
- 2018-02-27 CA CA3054754A patent/CA3054754A1/en active Pending
- 2018-02-27 TW TW107106465A patent/TW201841893A/zh unknown
- 2018-02-27 CN CN201880028604.3A patent/CN110582485B/zh active Active
- 2018-02-27 EP EP18712082.9A patent/EP3589618B1/en active Active
-
2019
- 2019-08-07 IL IL268565A patent/IL268565B/en unknown
- 2019-08-21 CO CONC2019/0009020A patent/CO2019009020A2/es unknown
- 2019-08-26 DO DO2019000221A patent/DOP2019000221A/es unknown
- 2019-08-28 CL CL2019002480A patent/CL2019002480A1/es unknown
- 2019-09-02 PH PH12019501999A patent/PH12019501999A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018228651A1 (en) | 2019-08-29 |
AU2018228651B2 (en) | 2020-12-17 |
TW201841893A (zh) | 2018-12-01 |
KR20190123307A (ko) | 2019-10-31 |
IL268565B (en) | 2022-06-01 |
BR112019018028A2 (pt) | 2020-03-24 |
EP3589618B1 (en) | 2022-12-28 |
US20190381010A1 (en) | 2019-12-19 |
KR102403176B1 (ko) | 2022-05-27 |
SG11201907546WA (en) | 2019-09-27 |
CN110582485A (zh) | 2019-12-17 |
ES2938269T3 (es) | 2023-04-05 |
PE20191535A1 (es) | 2019-10-23 |
JOP20190192A1 (ar) | 2019-08-08 |
EP3589618A1 (en) | 2020-01-08 |
UY37622A (es) | 2018-09-28 |
CL2019002480A1 (es) | 2019-11-29 |
JP6857254B2 (ja) | 2021-04-14 |
US10966961B2 (en) | 2021-04-06 |
JP2020509033A (ja) | 2020-03-26 |
PH12019501999A1 (en) | 2020-06-15 |
CA3054754A1 (en) | 2018-09-07 |
IL268565A (en) | 2019-09-26 |
DOP2019000221A (es) | 2019-11-15 |
WO2018158212A1 (en) | 2018-09-07 |
CR20190391A (es) | 2019-10-17 |
MX2019010218A (es) | 2019-10-21 |
CN110582485B (zh) | 2023-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
ECSP20040257A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
CO2020005887A2 (es) | Compuestos policíclicos como inhibidores alostéricos de shp2 | |
CO2017011851A2 (es) | Compuestos novedosos | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
UY37645A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
CL2013000304A1 (es) | Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor. | |
BR112016012146A2 (pt) | Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos | |
CL2019003398A1 (es) | Inhibidores pirazólicos de magl. | |
UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
BR112017009012A2 (pt) | derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso | |
UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
UY35747A (es) | Derivados sustituidos de fenilalanina | |
UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
CO2019009020A2 (es) | Derivados de pirazol como inhibidores de bromodominio. | |
CR20170513A (es) | Derivados de pirazol útiles como inhibidores de proteína activadora de 5-li-poxigenasa (flap). | |
UY35745A (es) | Derivados sustituidos de fenilalanina | |
CL2017002803A1 (es) | Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
CL2018002368A1 (es) | Formulaciones de oritavancina |